Cargando…

Auto-antibodies against type I IFNs are associated with severe COVID-19 pneumonia

Detalles Bibliográficos
Autores principales:	Zhou, Weilin, Wang, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7908001/ https://www.ncbi.nlm.nih.gov/pubmed/33637681 http://dx.doi.org/10.1038/s41392-021-00514-6

Ejemplares similares

Type I IFN deficiency: an immunological characteristic of severe COVID-19 patients
por: Wang, Zhenling, et al.
Publicado: (2020)

Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs
por: Bastard, Paul, et al.
Publicado: (2022)

Auto-antibodies against type I IFNs in > 10% of critically ill COVID-19 patients: a prospective multicentre study
por: Arrestier, Romain, et al.
Publicado: (2022)

Add on the next level—the time point of the type I IFN response orchestrates the immune response
por: Wedekind, Angela, et al.
Publicado: (2020)

Single cell RNA and immune repertoire profiling of COVID-19 patients reveal novel neutralizing antibody
por: Li, Fang, et al.
Publicado: (2020)

Potential mechanisms by which impaired ketogenesis links metabolism to T‐cell dysfunction in patients with severe COVID‐19
por: Wang, Bin, et al.
Publicado: (2022)

Inflammatory markers and auto-Abs to type I IFNs in COVID-19 convalescent plasma cohort study
por: Cognasse, Fabrice, et al.
Publicado: (2022)

Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine
por: Bastard, Paul, et al.
Publicado: (2021)

COVID-19: treating and managing severe cases
por: Ai, Jingwen, et al.
Publicado: (2020)

Type I interferon signaling deficiency results in dysregulated innate immune responses to SARS‐CoV‐2 in mice
por: Ogger, Patricia P., et al.
Publicado: (2022)

Unraveling the Dynamics of Antibody-Antigen Interaction by DNA Origami
por: Nie, Zhou
Publicado: (2020)

Autoantibodies against type I IFNs in patients with critical influenza pneumonia
por: Zhang, Qian, et al.
Publicado: (2022)

Posterior Reversible Encephalopathy Syndrome in Acute COVID-19 Pneumonia
por: Donaldson, Laura, et al.
Publicado: (2021)

COVID-19 and Tuberculosis
por: Yang, Heng, et al.
Publicado: (2020)

Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain
por: Troya, Jesús, et al.
Publicado: (2021)

Clinical Challenges with Hypervirulent Klebsiella Pneumoniae (hvKP) in China
por: Chen, Yanzhu, et al.
Publicado: (2021)

Combating COVID-19 with Chloroquine
por: Hong, Wanjin
Publicado: (2020)

Opsonizing antibodies mediated SARS‐CoV‐2 entry into monocytes leads to inflammation
por: Yao, Tong, et al.
Publicado: (2022)

Development of Antibody‐Directed Therapies: Quo Vadis?
por: Rodrigues, Tiago, et al.
Publicado: (2018)

Role of antibodies in vaccine-mediated protection against tuberculosis
por: Dieli, Francesco, et al.
Publicado: (2022)

Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia
por: Zhang, Qian, et al.
Publicado: (2022)

The putative mechanism of lymphopenia in COVID-19 patients
por: Wang, Xinling, et al.
Publicado: (2022)

Chest computed tomography characteristics of critically ill COVID-19 patients with auto-antibodies against type I interferons
por: Rapnouil, Baptiste Lafont, et al.
Publicado: (2023)

A promising vaccine candidate against COVID-19
por: Wang, Xiwei, et al.
Publicado: (2020)

Genetic tracing of HCoV-19 for the re-emerging outbreak of COVID-19 in Beijing, China
por: Yang, Jing, et al.
Publicado: (2020)

Pandemic number five – Latest insights into the COVID-19 crisis
por: Häfner, Sophia Julia
Publicado: (2020)

Potential treatment of COVID-19 by inhibitors of human dihydroorotate dehydrogenase
por: Xu, Yechun, et al.
Publicado: (2020)

The Application of Corticosteroids in COVID-19: A Two-edged Sword
por: Li, Na, et al.
Publicado: (2020)

What we have learned from COVID-19 pandemic?
por: Chen, Hsiu-Hsi, et al.
Publicado: (2021)

Single-cell transcriptomics reveals neuroinflammation in severe COVID-19
por: Lemprière, Sarah
Publicado: (2021)

Surrogate cytokine agonists: promising agents against COVID-19
por: Lin, Zemin, et al.
Publicado: (2022)

Prevention and treatment of COVID‐19 disease by controlled modulation of innate immunity
por: Schijns, Virgil, et al.
Publicado: (2020)

Real Nano “Light Vaccine” Will Benefit to COVID-19 Pandemic Control
por: Yang, Jianshe
Publicado: (2021)

Auto-anticorps anti-interférons de type I et COVID-19 sévère
por: Bastard, Paul, et al.
Publicado: (2021)

Pralidoxime and pesticide poisoning: A question of severity?
por: Walton, Emma Louise
Publicado: (2016)

Autoantibodies against type I IFNs in patients with life-threatening COVID-19
por: Bastard, Paul, et al.
Publicado: (2020)

A next‐generation vaccine for broader and long‐lasting COVID‐19 protection
por: Xi, Jinxiang, et al.
Publicado: (2022)

Neutrophil activation and neutrophil extracellular traps (NETs) in COVID‐19 ARDS and immunothrombosis
por: Cesta, Maria Candida, et al.
Publicado: (2022)

Early and Rapid Identification of COVID-19 Patients with Neutralizing Type I Interferon Auto-antibodies
por: Akbil, Bengisu, et al.
Publicado: (2022)

Targeting multiple epitopes on the spike protein: a new hope for COVID-19 antibody therapy
por: Sun, Yeping, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_n1g3h8n8vv6kspmosa80u689iq